Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;50(5):712-724.
doi: 10.1002/eji.201948457. Epub 2020 Feb 10.

CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma

Guangna Liu  1 , Wei Rui  1 , Hongli Zheng  1 , Daosheng Huang  1 , Fei Yu  2 , Yuewei Zhang  2 , Jiahong Dong  2 , Xueqiang Zhao  1 , Xin Lin  1   3
Affiliations
Free article

CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma

Guangna Liu et al. Eur J Immunol. 2020 May.
Free article

Abstract

Unlike hematological malignancies, solid tumors have proved to be less susceptible to chimeric antigen receptor (CAR)-T cell therapy, which is partially caused by reduced accumulation of therapeutic T cells in tumor site. Since efficient trafficking is the precondition and pivotal step for infused CAR-T cells to exhibit their anti-tumor function, strategies are highly needed to improve the trafficking ability of CAR-T cells for solid tumor treatment. Here, based on natural lymphocyte chemotaxis theory and characteristics of solid tumor microenvironments, we explored the possibility of enhancing CAR-T cell trafficking by using chemokine receptors. Our study found that compared with other chemokines, several CXCR2 ligands showed relatively high expression level in human hepatocellular carcinoma tumor tissues and cell lines. However, both human peripheral T cells and hepatocellular carcinoma tumor infiltrating T cells lacked expression of CXCR2. CXCR2-expressing CAR-T cells exhibited identical cytotoxicity but displayed significantly increased migration ability in vitro. In a xenograft tumor model, we found that expressing CXCR2 in CAR-T cells could significantly accelerate in vivo trafficking and tumor-specific accumulation, and improve anti-tumor effect of these cells.

Keywords: CAR-T; CXCR2; Chemokine; Immunotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Guo, Y., Wang, Y. and Han, W., Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects. J. Immunol. Res. 2016. 2016: 3850839.
    1. Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E. et al., A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006. 12: 6106-6115.
    1. Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S. and Paulos, C. M., CAR T cells in solid tumors: blueprints for building effective therapies. Front Immunol 2018. 9: 1740.
    1. Hughes, C. E. and Nibbs, R. J. B., A guide to chemokines and their receptors. FEBS J. 2018. 285: 2944-2971.
    1. Beck, L. A., Tancowny, B., Brummet, M. E., Asaki, S. Y., Curry, S. L., Penno, M. B., Foster, M. et al., Functional analysis of the chemokine receptor CCR3 on airway epithelial cells. J. Immunol. 2006. 177: 3344-3354.

Publication types

MeSH terms

LinkOut - more resources